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Purpose - To systematically review evidence regarding the association of multi-
parametric biomarkers with clinical outcomes and their capacity to explain relevant 
subcompartments of gliomas. 
 
Materials and Methods - Scopus database was searched for original journal papers from 
January 1st, 2007 to February 20th, 2017 according to PRISMA. Four hundred forty-nine 
abstracts of papers were reviewed and scored independently by two out of six authors. 
Based on those papers we analyzed associations between biomarkers, subcompartments 
within the tumor lesion, and clinical outcomes.  From all the articles analyzed, the twenty-
seven papers with the highest scores were highlighted to represent the evidence about MR 
imaging biomarkers associated with clinical outcomes. Similarly, eighteen studies 
defining subcompartments within the tumor region were also highlighted to represent the 
evidence of MR imaging biomarkers. Their reports were critically appraised according to 
the QUADAS-2 criteria. 
 
Results – It has been demonstrated that multi-parametric biomarkers are prepared for 
surrogating diagnosis, grading, segmentation, overall survival, progression-free survival, 
recurrence, molecular profiling and response to treatment in gliomas. Quantifications and 
radiomics features obtained from morphological exams (T1, T2, FLAIR, T1c), PWI 
(including DSC and DCE), diffusion (DWI, DTI) and chemical shift imaging (CSI) are 
the preferred MR biomarkers associated to clinical outcomes. Subcompartments relative 
to the peritumoral region, invasion, infiltration, proliferation, mass effect and pseudo 
flush, relapse compartments, gross tumor volumes, and high-risk regions have been 
defined to characterize the heterogeneity. For the majority of pairwise co-occurrences, 
we found no evidence to assert that observed co-occurrences were significantly different 
from their expected co-occurrences (Binomial test with False Discovery Rate correction, 
α=0.05). The co-occurrence among terms in the studied papers was found to be driven by 
their individual prevalence and trends in the literature. 
 
Conclusion - Combinations of MR imaging biomarkers from morphological, PWI, DWI 
and CSI exams have demonstrated their capability to predict clinical outcomes in different 
management moments of gliomas. Whereas morphologic-derived compartments have 
been mostly studied during the last ten years, new multi-parametric MRI approaches have 
also been proposed to discover specific subcompartments of the tumors. MR biomarkers 
from those subcompartments show the local behavior within the heterogeneous tumor and 
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Purpose - To systematically review evidence regarding the association of multi-parametric biomarkers 
with clinical outcomes and their capacity to explain relevant subcompartments of gliomas. 
 
Materials and Methods - Scopus database was searched for original journal papers from January 1st, 2007 
to February 20th, 2017 according to PRISMA. Four hundred forty-nine abstracts of papers were reviewed 
and scored independently by two out of six authors. Based on those papers we analyzed associations 
between biomarkers, subcompartments within the tumor lesion, and clinical outcomes.  From all the articles 
analyzed, the twenty-seven papers with the highest scores were highlighted to represent the evidence about 
MR imaging biomarkers associated with clinical outcomes. Similarly, eighteen studies defining 
subcompartments within the tumor region were also highlighted to represent the evidence of MR imaging 
biomarkers. Their reports were critically appraised according to the QUADAS-2 criteria.  
 
Results – It has been demonstrated that multi-parametric biomarkers are prepared for surrogating diagnosis, 
grading, segmentation, overall survival, progression-free survival, recurrence, molecular profiling and 
response to treatment in gliomas. Quantifications and radiomics features obtained from morphological 
exams (T1, T2, FLAIR, T1c), PWI (including DSC and DCE), diffusion (DWI, DTI) and chemical shift 
imaging (CSI) are the preferred MR biomarkers associated to clinical outcomes. Subcompartments relative 
to the peritumoral region, invasion, infiltration, proliferation, mass effect and pseudo flush, relapse 
compartments, gross tumor volumes, and high-risk regions have been defined to characterize the 
heterogeneity. For the majority of pairwise co-occurrences, we found no evidence to assert that observed 
co-occurrences were significantly different from their expected co-occurrences (Binomial test with False 
Discovery Rate correction, α=0.05). The co-occurrence among terms in the studied papers was found to be 
driven by their individual prevalence and trends in the literature.  
 
Conclusion - Combinations of MR imaging biomarkers from morphological, PWI, DWI and CSI exams 
have demonstrated their capability to predict clinical outcomes in different management moments of 
gliomas. Whereas morphologic-derived compartments have been mostly studied during the last ten years, 
new multi-parametric MRI approaches have also been proposed to discover specific subcompartments of 
the tumors. MR biomarkers from those subcompartments show the local behavior within the heterogeneous 




Gliomas are tumors that arise from glial cells. Types of glioma include astrocytoma, oligodendroglioma, 
and a number of diagnostic categories classified as other gliomas and mixed neuronal-glial tumors. A grade 
of malignancy, ranging from I to IV, is assigned to each specific tumor class; grade I and II tumors are 
known as low-grade gliomas, while grade III and IV tumors are considered high-grade gliomas [1]. 
According to the report in the United States from 2008 to 2012 [2], gliomas represent approximately 27% 
of all central nervous system (CNS) tumors in adults and 53% of CNS tumors in children and adolescents 
aged 0-14 years in the United States. Most importantly, 80% of malignant tumors are gliomas. In particular, 
glioblastoma, a high-grade glioma with predominantly astrocytic differentiation, accounts for the majority 
of gliomas (55%) and 46% of all malignant CNS tumors and carries the worst prognosis. 
Gliomas and especially high-grade gliomas are heterogeneous masses at phenotypic, physiologic, and 
genomic levels [3,4,5]. Such condition implies difficulties in standard of care definitions. Multiple research 
studies have tackled this heterogeneity attempting to define biomarkers relative to clinical outcomes by 
delineating regions of interest in the tumors.  
MR imaging biomarkers are biological features extracted from MR imaging able to support decisions 
during the management of patients. Multi-parametric image biomarkers are compositions of 
complementary image biomarkers willing to represent the patients’ conditions better than single 
biomarkers. Tumor subcompartments are areas of differing underlying biology within the heterogeneous 
tumor region where image biomarkers could provide clinically relevant information. 
This paper reports a literature systematic review of evidence regarding the definition of multi-parametric 
MR imaging-based biomarkers associated with clinical outcomes and their capacity to explain relevant 
subcompartments in patients with glioma. We sought to address two main clinical questions in this 
population: (1) which multi-parametric MR imaging biomarkers can be associated with clinical outcomes? 
and (2) which subcompartments have been defined in multi-parametric MR images? For each question, we 
will analyze the journal papers published in a period of 10 years that used multi-parametric MR image 
biomarkers to study clinical outcomes and patient conditions. We gave special attention to those journals 
including papers presenting the definition of subcompartments within the tumor lesion based on multiple 
MR images and their relation with clinical outcomes.  
2. Materials and Methods 
2.1 Evidence acquisition 
This systematic review was performed after collecting published scientific documents until February 20th, 
2017, reporting original studies where multi-parametric MR biomarkers were related to clinical outcomes 
and/or patient conditions. The identification of documents was mainly achieved using the Scopus advanced 
search engine to query the Scopus citation database (1083 papers). The general terms of the query were 
magnetic resonance, glioma, multi-parametric MR biomarker and subcompartment. These terms were 
instantiated in specific terms building a Scopus advanced query that was executed on February 20th, 2017 
(see Table S1a in Supplementary material for details). A query to PubMed database through its “PubMed 
Advanced Search Builder” and its thesaurus called MeSH (Medical Subject Headings) added 83 references 
to the list of identified papers of the study. 
Focusing on the query logic, at the initial point we started with the following selection criteria: all papers 
that contain the term “magnetic resonance imaging” (accepting also “mr”, “mri” or “perfusion”) together 
with the word "glioma or glioblastoma" in its title, abstract or keywords. Then, we were adding more 
conditions aiming to adjust as much as possible the obtained results. Going deeply into the query executed 
(showed in Table S1a), it can be divided into 5 different sub-queries (broken down in Table S1b of the 
Supplementary File), following these patterns: 
1. Studies of multiparametric MRI and/or subcompartments in gliomas  
2. Studies of MRI for predicting clinical outcomes or conditions in patients with glioma 
3. Studies of vascularity MRI in gliomas  
4. Studies of MRI and molecular profiling in gliomas 
5. Studies of contrast-enhanced MRI biomarkers in gliomas 
We specified exclusion criteria for those papers classified as reviews in the Scopus database (using the 
field “doctype”). Lastly, there were considered only articles written in English language. 
After filtering from 1st, 2007 to February 20th, 2017 and eliminating duplicates we screened 815 records 
by reviewing titles. In the next step, we excluded 166 papers by consensus between authors JGG and MOS 
after reviewing carefully their titles; the main reason was the lack of using magnetic resonance imaging 
techniques, but there were others like using other techniques (CT, SPECT, etc.), some case reports and 
others were out of our scope. Then we cope with 649 abstracts and all of them were reviewed by JGG and 
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MOS, discarding 200 because they did not associate multiple biomarkers to clinical outcomes or patient 
conditions.  
At that moment, we decided to make an extensive review of all the selected abstracts in order to extract the 
maximum information that we consider important for our study. Thus, two out of six authors (from JGG, 
MOS, EFG, JJA, APG and RSR) evaluated the selected 449 studies by a set of features relative to: the 
population, research design (retrospective vs. prospective study; transversal vs. longitudinal study and 
evaluation criteria), diagnosis, clinical outcome, treatment, management time point at the MR exam, MR 
field strength, MR sequence, analysis techniques, MR biomarkers and tumor subcompartments. The catalog 
of values for each feature was prospectively defined from the keywords used in the abstracts of the papers. 
The valuable and detailed information collected at this point has been the basis of this review.  
Table1 summarizes the variables extracted from the 449 abstracts included in the qualitative synthesis. The 
table shows for each feature the number of abstracts with information and the categorized values list. For 
clarity, only the most frequent values for the variables are included in the table. For a complete list of 
variables, readers may visit the supplementary material. The file that contains the characterized data for all 




The Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) process for reporting 
included and excluded studies was adhered to. The flow diagram of the process is shown in Fig 1.  
Fig 1. Fig1_flowchart 
 
2.2 Assessment of study quality 
We evaluated in more detail the final set of 45 highlighted papers for the considered questions by the 
Quality Assessment of Diagnostic Accuracy Studies (QUADAS-2) criteria [6]. The overall quality of the 
studies was fair to good, with low risk of bias and concerns about applicability (Fig. 2). Table S5 of 
Supplementary File provides the detailed analysis of risk of bias and applicability concerns. 
Fig 2. Fig2_quadas2 
 
2.3 Qualitative synthesis  
During the review, the authors scored every abstract in a 0 to 10 scale given the relevance of the previously 
defined features for our clinical questions. The 45 papers with scores equal or higher than 8 were 
highlighted. From them, 18 defined tumor subcompartments and the other 27 did not. We analyzed the 
quality of our study using QUADAS-2 criteria over the highlighted papers, as mentioned in the previous 
section “assessment of study quality”. 
In the procedure to assign a score to a paper, the main variables taking into consideration have been: clinical 
outcomes, MR biomarkers, and subcompartments. These three features have had the biggest weight of the 
score, but the others have also been important to get the final value. For example, if one study has a 
population of 5 patients and another similar study carries out 50 patients, the later get a better score. In 
short, the score has to be understood as a measure of the relevance of every paper related to the clinical 
question to be answered. 




3.1 Populations studied 
Most of the papers (317 out of 449, 70%) assessed in the review were targeted to adults and the median (± 
mean absolute deviation) number of individuals in their studies was 37±17. Additionally, it is worth to 
mention the high number of studies addressing glioblastoma (169 out of 449, 38%) and, more generally, 
high-grade gliomas (278 out of 449, 62%). Most study designs were transversal (366 out of 449, 82%) and 
retrospective (371 out of 449, 83%). Table S2 in Supplementary File gives a complete number of the target 
populations, a number of individuals, diagnoses and study designs of assessed studies. 
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3.2 MRI studies 
Most of the procedures were carried out before the surgical intervention (199 out of 449, 44%). The second 
most studied time point was at follow-up (51 out of 449 articles, 11%). Finally, only 25 studies were carried 
out during recurrence (6%). In total, there were 142 studies performed after surgery (32%). 
Most papers did not report the used MR field strength in the abstract. There was a high variability in the 
type of MR sequences included in the studies. Most studies focused on functional images, including 
perfusion (PW) (174 studies, 39%) and diffusion-weighted (DW) images (117 studies, 26%). Standard 
morphologic MR images were also routinely used (182 out of 449, 41%). See Table S3 in Supplementary 
File for details. 
 
3.3 Clinical outcomes and treatments 
Most papers defined overall survival (OS) as the main response variable of the study (177 out of 449, 39%). 
Fewer studies were able to study progression-free survival (PFS) (41 studies, 9%), time to progression 
(TTP) (3 studies, <1%), recurrence (33 studies, 7%), tumor progression (12 studies, 3%) and RANO criteria 
(2 studies, <1%). Some studies also included molecular profiling and biological functions as response 
variables (51 out of 449, 11%). As expected, diagnosis and grading were clinical outcomes highly 
evaluated, appearing each one in 104 papers (23% each one). 
Most of the studies did not directly refer to a specific treatment. This was in part due to the high number of 
preoperative studies. Nevertheless, it is likely that most postoperative patients received the standard 
treatment based on radiation therapy and Temozolomide [7]. Bevacizumab (with 25 studies) and 
Temozolomide (with 15 studies) were the most cited specific treatments. Table S4 in Supplementary File 
shows the clinical outcomes and treatments of the studies assessed in this review. 
 
3.4 Which multi-parametric MR imaging biomarkers can be associated with clinical outcomes? 
Imaging biomarkers were classified into two groups: biomarkers based on feature extraction methods and 
biomarkers for specific MR-sequences. Biomarkers based on feature extraction methods are independent 
of the MR sequence and are related to volumes, areas, texture features, shapes and image moments from 
morphologic or functional images (3rd to 11th rows of Table S6 in Supplementary File). Besides, biomarkers 
for specific MR sequences were extensively used in the reviewed literature and includes the quantification 
of Cerebral Blood Volume (CBV) (112 studies), Ktrans (31 studies) and ADC (79 studies), among others. 
Moreover, authors defined specific biomarkers based on metabolite concentration or ratios extracted from 
Chemical Shift Imaging (CSI). Table S6 summarizes the MR imaging biomarkers used in the studies 
selected for this review. 
Figure 3 summarizes the relationships found among MR imaging biomarkers and the most prevalent clinical 
outcomes. In this graphical network, the thickness of the edges is linearly relative to the number of papers 
where the concepts appear connected; these connections have been calculated from the co-occurrence 
matrix between all pairs of terms showed in the graph, using R routines [64].  
Fig 3. Fig3_ subrogatedbiomarkers 
In that context, there were observed some strong co-occurrences between biomarkers and clinical outcomes 
as well as biomarkers with each other. Specifically, CBV biomarker was used several times in combination 
with ADC (26 papers, 5.7%) and spectroscopic metabolites, such as choline (Cho) and creatine (Cr) (20 
and 18 papers, respectively). These co-occurrences were not significantly different from their expected co-
occurrences given by their individual prevalence (Binomial test with False Discovery Rate correction, 
α=0.05). Nevertheless, this high prevalence may reflect the search for complementary information provided 
by the biomarkers. Whereas CBV indicates vascularization of tumor region [8], ADC is a biomarker 
grading cellular density and integrity, and therefore related to tumor growth and necrosis [9]. Moreover, 
metabolites are the functional fingerprint of protein functions, genetic variations and environmental 
effects [10]. 
In view of the results, overall survival and PFS were evaluated mainly by perfusion biomarkers, such as 
CBV (OS-CBV in 17 papers, 3.7%; PFS-CBV in 11 papers, 2.4%). ADC was also used for survival analysis 
(OS-ADC in 8 papers, 1.7%), while there were fewer studies of survival based on the MR spectroscopic 
analysis of tumor metabolites. Progression-free survival was mainly analyzed by ADC, CBV, N-acetyl-
aspartate (NAA), Glutamate (Glu), Glutamine (Gln) and Myo-inositol (mI). Moreover, the association of 
molecular profiling with perfusion biomarkers was largely studied by the reviewed papers. Additionally, 
the association of mI, NAA, Cho, lactate, and lipids with molecular profiling was extensively studied as 
well. 
Table 3. Table3_biomarkers 
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Twenty-seven highlighted journal papers were included in Table 3 [11-37]. All clinical outcomes were 
studied, at least once, by the combination of three or more types of MR exams. Twelve papers associated 
MR biomarkers to progression, recurrence or survival. From them, 9 extracted morphologic biomarkers, 7 
used perfusion coefficients, 5 used diffusion parameters and 4 quantified different MRS/CSI metabolites. 
Apart from that, morphologic images and perfusion coefficients were used in 3 studies of molecular 
profiling, whereas ADC was used in 2 and MRS/CSI in 1, respectively. Morphologic features were used in 
5 out of the 6 studies for tumor grading to discriminate gliomas after manual segmentation, whereas 
MRS/CSI was also used in 4 of them. Moreover, only 2 studies performed segmentations as a primary goal 
of the multi-parametric study: the first one combined morphologic images (T1, T2, FLAIR and T1c), while 
the second one combined them with PW and DW imaging studies. Only O’Neill et al. [19] studied response 
to treatment (VEGF Trap) using morphologic images, DCE, DWI, and FDG-PET.  Besides, only Durst et 
al. [36] estimated nuclear density to predict tumor infiltration in a study from morphologic, perfusion and 
diffusion images. It is also relevant to highlight that radiomics and radiogenomics techniques were applied 
during the last years to define relevant biomarkers from MR images in gliomas. 
 
3.5 Which subcompartments have been defined in multi-parametric MR images? 
Morphologic regions (such as tumor, edema, and necrosis), broad volumes of interest, intensity-based 
regions (enhanced tumor, non-enhanced tumor) or regions from functional images (such as contrast-
enhanced tumor or hypoperfused tumor volume) guided the majority of the studies. Several studies defined 
morphological subcompartments of the tumor, such as the center of the tumor (8 studies), the rim of the 
tumor (3 studies) or the peritumoral region (17 studies). Others focused on treatment-response 
compartments, such as radiation-induced edema (1 study) and resection cavities (3 studies). Different 
conditions of the local regions (e.g. specifically hypoxia and mass effect) and biological processes 
associated with cancer, such as infiltration and vascular disruption, defined functional regions of the tumors. 
Less specific but still focused on defining subcompartments were those studies showing heterogeneous 
lesions in contrast to homogeneous lesions. As expected, specific locations of the tumor were also studied: 
locations involving basal ganglia, corpus callosum, caudate putamen or close to the cerebrospinal fluid. 
Table S7 in Supplementary File includes all references to subcompartments and regions defined in the 
reviewed papers. Additionally, Table S8 in Supplementary File lists the analysis techniques and statistical 
tests performed by the studies included in this review.  
Figure 4 shows the graphical network of the relationships among subcompartments, MR imaging 
biomarkers and clinical outcomes. Although the most prevalent regions in the eligible studies are relative 
to the morphology of the tumor, several studies defined specific regions associated with response to 
treatment and the tumor characterization at different levels. It is important to mention that the obtained co-
occurrences were not significantly different from their expected.  
Fig 4. Fig4_subcompartments 
The question “which subcompartments have been defined in multi-parametric MR images?” is answered 
in S2 Table [38-55]. Whereas typical morphologic-derived compartments, such as enhancing tumor, edema 
and necrosis have been studied during the last decades, more specific subcompartments or regions have 
been defined only in multi-parametric studies. The peritumoral region has been widely studied with 
different morphologic, perfusion, diffusion and metabolic biomarkers for either diagnosis, grading or 
survival analysis. Moreover, specific compartments such as relapse compartments, gross tumor volumes, 
high-risk volumes, and non-specific clustering compartments have been defined for overall survival, 
progression-free survival and recurrence. Besides, Christoforidis et al. [54] defined tumoral pseudoblush 
as a marker for increased tumoral microvascularity. Finally, the study to connect the subcompartments with 
high levels of invasion, infiltration, proliferation, mass effect and FLAIR hyperintensity with different 
molecular profiles of gliomas was of special interest to this review. 
Table 4. Table4_subcompartments 
4. Discussion 
Multiple image biomarkers have demonstrated their association to clinical outcomes of glioma, including 
diagnosis, grading, segmentation, overall survival, progression-free survival, recurrence, molecular 
profiling and response to treatment. Combinations of biomarkers, such as PW, DW, and CSI, with 
radiomics features from morphological exams (T1, T2, FLAIR, and T1c) are the preferred MR biomarkers 
in the state of the art. 
There is a trend to delineate subcompartments, relative to tumor progression and specific biological 
processes in gliomas. As it is said in Hanahan [56], the biology of a tumor can only be understood by 
studying the individual specialized cell types within it, and taking into consideration the “tumor 
microenvironments” that the cells construct during the course of multistep tumorigenesis. In addition to the 
characterization of the peritumoral region, relapse compartments, gross tumor volumes, high-risk volumes, 
 10 
and non-specific clustering compartments have been defined for overall survival, progression-free survival 
and recurrence. Besides, subcompartments within gliomas with high invasion, infiltration, proliferation, 
mass effect and pseudoflush are markers of differential molecular profiles and tissue characterization. 
Potential clinical benefits of incorporating MR imaging biomarkers and delimiting accurately the different 
subcompartments to the clinical practice include advancements in surgery and radiotherapy planning, 
adjuvant treatment selection, assessment of response, early recurrence detection and selection of subsequent 
therapies. Moreover, this integrated approach will contribute to a better characterization of glioma 
subgroups, identification of new circulating biomarkers, and identification of new targets for the treatment 
of patients with glioma.  
The definition of accurate multi-parametric MR biomarkers for specific tumor regions may help on the 
interpretation of treatment response in early stages, allowing active planning during multidisciplinary 
treatments. Macdonald’s [57] and RANO criteria [58] based on bi-dimensional measurements and WHO 
standards for reporting results of cancer treatment may not reflect non-enhancing patterns of infiltration, 
neither the effect of specific therapies (such as anti-angiogenic therapies on high-grade gliomas) [59]. 
Moreover, manual procedures to delineate complex patterns are not plausible. Despite improvements made 
by the RANO criteria, the delineation of subcompartments based on multi-parametric MR biomarkers to 
routine practice may achieve a more accurate characterization of tumors and could be very helpful in the 
difficult task of depicting the tumor heterogeneity. 
With the objective to achieve a more reliable characterization of brain tumor biology at the molecular level, 
MRI can be combined with another diagnostic technique called positron emission tomography (PET). PET 
can provide this detailed metabolic information, which when combined with the high spatial and contrast 
resolution of MRI could help tailor treatment regimens at an early stage [60].  
By using radioactive tracers, PET can provide quantitative information of cellular activity and metabolism 
of the tumor tissue. Amino acid PET tracers are recommended as a complement to MRI by current 
guidelines in brain tumor imaging. This have proven promising for defining true tumor volume and 
differentiating viable tumor tissue from postoperative changes or radiation necrosis, and as a guide to select 
the best biopsy sites in gliomas.  
Hybrid PET/MRI have the potential to improve the diagnostic accuracy compared to MRI alone. Castiglioni 
[61] describes that hybrid PET/MRI represents an innovative diagnostic technology for non-invasive in 
vivo imaging of cancer; the preliminary results are showing potentials to enter the technique in the clinical 
setting. It also represents a reduction of radiation exposure which implies benefits for patients. 
PET/MRI tomographs open new perspectives for clinical and research applications and attract a large 
interest among the medical community. This new hybrid modality is expected to play a pivotal role in a 
number of clinical applications [62]. Finally, as Marner [63] stress in their article, there are still a number 
of caveats in using a PET/MRI scanner, but solutions to overcome the challenges are being developed. 
It is important to note that most reviewed papers did not provide molecular profiling (i.e., IDH mutation 
and 1p/19q codeletion status) to use the 2016 World Health Organization classification of tumors of the 
CNS (WHO CNS) [1]. 
5. Conclusion 
Combinations of MR imaging biomarkers from morphological, PWI, DWI and CSI exams have 
demonstrated their capability to predict clinical outcomes in different management moments of gliomas. 
Whereas morphologic-derived compartments have been mostly studied during the last ten years, new multi-
parametric MRI approaches have also been proposed to discover specific subcompartments of the tumors. 
MR biomarkers from those subcompartments show the local behavior within the heterogeneous tumor and 
may quantify the prognosis and response to treatment of gliomas. 
The understanding of the underlying behavior of the different tumor tissues in terms of their distribution 
and topology along the lesion and the specific properties of sub-regions is mandatory to improve therapy 
planning. The possibility to know which parts of the homogeneous tumor are more aggressive may provide 
critical information to improve the survival of the patients. 
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Fig 1. Flow diagram for systematic reviews and meta-analysis (PRISMA) showing the 
outcome of the initial and additional searches resulting in the full studies included in the 
review. 
Fig 2. Results for risk of bias and concerns about applicability using the QUADAS-2 
criteria.   
Fig 3. Graphical network with the relationships among MR imaging biomarkers and 
clinical outcomes. The thickness of the edges is linearly related to the number of papers 
where the concepts appear connected. 
Fig 4. Graphical network with the relationships among subcompartments, MR imaging 
biomarkers, and clinical outcomes. The thickness of the edges is linearly related to the 
number of papers where the concepts appear connected. 
 
Table legends 
Table 1. Data extracted from the 449 abstracts selected for qualitative synthesis. 
Table 2. Number of papers per each score after the author's revision. 
Table 3. Selected papers that use multi-parametric MR imaging biomarkers to predict 
clinical outcomes in gliomas. 
Table 4. Selected papers that define subcompartments and multi-parametric MR 
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